Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.40B | 1.05B | 1.23B | 1.27B | 1.22B |
Gross Profit | 753.36M | 551.31M | 770.75M | 806.28M | 781.07M |
EBITDA | 260.87M | 193.05M | 229.06M | 2.13B | 279.43M |
Net Income | 93.10M | 16.70M | 51.28M | 1.99B | 78.53M |
Balance Sheet | |||||
Total Assets | 2.62B | 2.89B | 2.78B | 3.64B | 3.25B |
Cash, Cash Equivalents and Short-Term Investments | 216.84M | 171.00M | 189.30M | 277.53M | 414.54M |
Total Debt | 227.30M | 204.14M | 163.49M | 267.14M | 156.71M |
Total Liabilities | 1.07B | 930.07M | 939.50M | 1.25B | 1.14B |
Stockholders Equity | 1.65B | 2.04B | 1.92B | 2.46B | 2.15B |
Cash Flow | |||||
Free Cash Flow | 34.45M | -45.89M | 69.81M | -160.04M | -139.23M |
Operating Cash Flow | 242.01M | 110.08M | 283.63M | 210.68M | 218.91M |
Investing Cash Flow | -192.36M | -145.22M | -256.05M | -370.28M | -523.74M |
Financing Cash Flow | -1.96M | 13.44M | -128.60M | 60.97M | -9.80M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
67 Neutral | HK$830.26M | 8.92 | 5.04% | 3.55% | 32.95% | 456.69% | |
52 Neutral | $7.53B | 0.32 | -61.76% | 2.28% | 16.60% | 1.56% | |
$1.28B | ― | -4.93% | 2.69% | ― | ― | ||
74 Outperform | HK$6.25B | 6.87 | 11.61% | 9.30% | -18.09% | -15.08% | |
73 Outperform | HK$1.86B | 3.05 | 18.33% | 4.84% | -9.95% | 67.56% | |
70 Outperform | HK$10.16B | 10.24 | 8.89% | 3.84% | 4.91% | -11.80% | |
67 Neutral | HK$12.76B | 24.41 | 5.88% | ― | -42.02% | -76.29% |
Lee’s Pharmaceutical Holdings Limited held its Annual General Meeting on May 22, 2025, where all proposed resolutions were passed. Key resolutions included the approval of audited financial statements, declaration of a final dividend, re-election of directors, and granting of mandates for share repurchase and issuance. The successful passing of these resolutions indicates strong shareholder support and positions the company for continued operational stability and strategic growth.
Lee’s Pharmaceutical Holdings Limited has announced its upcoming Annual General Meeting (AGM) scheduled for May 22, 2025, where shareholders will consider several key resolutions. These include the approval of audited financial statements, declaration of a final dividend, re-election of directors, and re-appointment of auditors. Additionally, the company seeks authorization to repurchase up to 10% of its issued shares, reflecting a strategic move to manage its share capital and potentially enhance shareholder value.